Literature DB >> 1757094

Identification of a mutation in the promoter region of the dystrophin gene in a patient with atypical Becker muscular dystrophy.

K M Bushby1, N J Cleghorn, A Curtis, I D Haggerty, L V Nicholson, M A Johnson, J B Harris, S S Bhattacharya.   

Abstract

We have identified 7 patients with Becker muscular dystrophy (BMD) in whom analysis of dystrophin by immunoblotting shows a full-sized molecule produced at reduced abundance compared with controls. They have no detectable deletion in their dystrophin cDNA. One patient presented atypically with unusually severe cramps as his only symptom for 25 years. These patients were investigated using the polymerase chain reaction (PCR) with 3 sets of primers within the promoter region of the dystrophin gene, followed by dot blot and restriction analysis. In the patient with the atypical history, one of the expected fragments on PCR failed to amplify. A large deletion was excluded by the finding of normally sized fragments on amplification with the other primer sets. The mutation was localised to the 3' end of the forward primer binding site by dot blot and restriction analysis. This result supports the hypothesis that, in patients with a full-sized dystrophin molecule produced at reduced abundance, the phenotype may result from a mutation in the promoter region of the dystrophin gene. The atypical history of the patient in whom this was detected adds to the variety of phenotypes now known to exist as BMD.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1757094     DOI: 10.1007/bf00206071

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  22 in total

1.  [A new x-chromosomal muscular dystrophy].

Authors:  P E BECKER; F KIENER
Journal:  Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr       Date:  1955

2.  Familial X-linked myalgia and cramps: a nonprogressive myopathy associated with a deletion in the dystrophin gene.

Authors:  S M Gospe; R P Lazaro; N S Lava; P M Grootscholten; M O Scott; K H Fischbeck
Journal:  Neurology       Date:  1989-10       Impact factor: 9.910

3.  Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy.

Authors:  L V Nicholson; M A Johnson; D Gardner-Medwin; S Bhattacharya; J B Harris
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

4.  Correlation of clinical and deletion data in Duchenne and Becker muscular dystrophy.

Authors:  S Hodgson; K Hart; S Abbs; J Heckmatt; E Rodillo; M Bobrow; V Dubowitz
Journal:  J Med Genet       Date:  1989-11       Impact factor: 6.318

5.  Prevalence and incidence of Becker muscular dystrophy.

Authors:  K M Bushby; M Thambyayah; D Gardner-Medwin
Journal:  Lancet       Date:  1991-04-27       Impact factor: 79.321

6.  Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy.

Authors:  E P Hoffman; K H Fischbeck; R H Brown; M Johnson; R Medori; J D Loike; J B Harris; R Waterston; M Brooke; L Specht
Journal:  N Engl J Med       Date:  1988-05-26       Impact factor: 91.245

7.  Dystrophin in skeletal muscle. II. Immunoreactivity in patients with Xp21 muscular dystrophy.

Authors:  L V Nicholson; K Davison; M A Johnson; C R Slater; C Young; S Bhattacharya; D Gardner-Medwin; J B Harris
Journal:  J Neurol Sci       Date:  1989-12       Impact factor: 3.181

8.  Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification.

Authors:  J S Chamberlain; R A Gibbs; J E Ranier; P N Nguyen; C T Caskey
Journal:  Nucleic Acids Res       Date:  1988-12-09       Impact factor: 16.971

9.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.

Authors:  A P Monaco; C J Bertelson; S Liechti-Gallati; H Moser; L M Kunkel
Journal:  Genomics       Date:  1988-01       Impact factor: 5.736

10.  Improved diagnosis of Becker muscular dystrophy by dystrophin testing.

Authors:  E P Hoffman; L M Kunkel; C Angelini; A Clarke; M Johnson; J B Harris
Journal:  Neurology       Date:  1989-08       Impact factor: 9.910

View more
  3 in total

1.  Brain- and muscle-type promoters of the dystrophin gene are selected in peripheral lymphocytes and Epstein Barr virus-transformed lymphoblastoid [correction of lymphoplastoid] cells.

Authors:  H Nishio; M Matsuo; Y Kitoh; N Narita; M Shimmoto; Y Suzuki; H Nakamura
Journal:  J Neurol       Date:  1993-12       Impact factor: 4.849

2.  A recombination event excludes the ROM1 locus from the Best's vitelliform macular dystrophy region.

Authors:  H Stöhr; B H Weber
Journal:  Hum Genet       Date:  1995-02       Impact factor: 4.132

3.  WGS and RNA Studies Diagnose Noncoding DMD Variants in Males With High Creatine Kinase.

Authors:  Leigh B Waddell; Samantha J Bryen; Beryl B Cummings; Adam Bournazos; Frances J Evesson; Himanshu Joshi; Jamie L Marshall; Taru Tukiainen; Elise Valkanas; Ben Weisburd; Simon Sadedin; Mark R Davis; Fathimath Faiz; Rebecca Gooding; Sarah A Sandaradura; Gina L O'Grady; Michel C Tchan; David R Mowat; Emily C Oates; Michelle A Farrar; Hugo Sampaio; Alan Ma; Katherine Neas; Min-Xia Wang; Amanda Charlton; Charles Chan; Diane N Kenwright; Nicole Graf; Susan Arbuckle; Nigel F Clarke; Daniel G MacArthur; Kristi J Jones; Monkol Lek; Sandra T Cooper
Journal:  Neurol Genet       Date:  2021-01-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.